医疗保险索赔队列中双膦酸盐使用未增加手术治疗长骨骨折后骨不连风险
该回顾性分析纳入2016至2019年医疗保险索赔中≥65岁接受手术治疗的长骨骨折患者111,343例,其中10,452例(9.4%)在1年内出现骨不连。在控制年龄、性别、种族、查尔森合并症指数和骨折类型后,双膦酸盐(OR 1.06,95%CI 0.99-1.12,P=0.101)及选择性雌激素受体调节剂/激素替代治疗(SERM/HRT)(OR 1.13,95%CI 0.93-1.36,P=0.218)均与骨不连无显著关联。作者认为骨科医生不应因担心骨不连而暂缓或延迟启动骨质疏松药物治疗。
要点
- 手术治疗长骨骨折后1年骨不连发生率为9.4%。
- 双膦酸盐使用与骨不连无显著关联(OR 1.06,95%CI 0.99-1.12)。
- SERM/HRT使用与骨不连无显著关联(OR 1.13,95%CI 0.93-1.36)。
核心结论
- 在医疗保险队列中,双膦酸盐或SERM/HRT的使用与手术治疗长骨骨折后1年骨折愈合状态无显著关联。
- 作者认为骨科医生不应因担心骨不连而暂缓或延迟启动骨质疏松药物治疗。
研究设计与样本
- 回顾性分析2016至2019年医疗保险索赔数据,纳入≥65岁接受手术治疗的长骨骨折患者。
- 通过连续索赔记录链接至骨折后1年以判定骨折愈合状态。
- 采用多变量逻辑回归模型分析药物与骨折愈合状态的关联,控制年龄、性别、种族、查尔森合并症指数和骨折类型。
主要发现
- 共纳入111,343例骨折,其中10,452例(9.4%)在1年内诊断为骨不连。
- 骨不连组较非骨不连组更年轻(79.8±8.3岁 vs 80.6±8.4岁,P<0.001)。
- 骨不连组白人比例更高(92.4% vs 90.9%,P<0.001)。
- 骨不连组查尔森合并症指数≥2的比例更高(50.9% vs 49.4%,P<0.001)。
- 骨不连组双膦酸盐使用更常见(12.2% vs 11.4%,P=0.017)。
关键数值与推荐
- 控制种族、年龄、性别和查尔森合并症指数后,双膦酸盐与骨不连无显著关联(OR 1.06,95%CI 0.99-1.12,P=0.101)。
- 控制种族、年龄、性别和查尔森合并症指数后,SERM/HRT与骨不连无显著关联(OR 1.13,95%CI 0.93-1.36,P=0.218)。
- 骨折后90天内使用双膦酸盐与骨不连无显著关联(OR 0.94,95%CI 0.86-1.03,P=0.175)。
- 用药时机不影响骨折愈合状态。
临床怎么用
- 作者认为骨科医生不应因担心骨不连而暂缓或延迟启动骨质疏松药物治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnosis of a fragility fracture represents an important intervention event for the initiation of medical osteoporosis treatments. However, it is unclear if osteoporosis medications increase the risk of nonunion if administered in the setting of acute fracture. The purpose of the present study was to investigate whether bisphosphonates or selective estrogen receptor modulators/hormone replacement therapy (SERM/HRT) are associated with nonunion following fracture in a Medicare population. METHODS: A retrospective analysis of Medicare claims from 2016 to 2019 was performed to identify patients ≥65 years of age who had a surgically treated long-bone fracture as identified with Current Procedural Terminology (CPT) codes and International Classification of Diseases, 10th Revision (ICD-10) codes. Successive claims were linked for each beneficiary through 1 year following the fracture to determine fracture union status. Multivariable logistic regression models were specified to identify the association between medications and fracture union status while controlling for age, sex, race, Charlson Comorbidity Index (CCI), and fracture type. RESULTS: Of the 111,343 included fractures, 10,452 (9.4%) were associated with a diagnosis of nonunion within 1 year. The nonunion group was younger (79.8 ± 8.3 versus 80.6 ± 8.4 years; p < 0.001), more likely to be White (92.4% versus 90.9%; p < 0.001), and more likely to have a CCI of ≥2 (50.9% versus 49.4%; p < 0.001). Bisphosphonate use was more common in the nonunion group (12.2% versus 11.4%; p = 0.017). When controlling for race, age, sex, and CCI, neither bisphosphonates (OR, 1.06 [95% CI, 0.99 to 1.12]; p = 0.101) nor SERM/HRT (OR, 1.13 [0.93 to 1.36]; p = 0.218) were associated with nonunion. Bisphosphonate use within 90 days post-fracture was not significantly associated with nonunion (OR, 0.94 [95% CI, 0.86 to 1.03]; p = 0.175), and the timing of medication administration did not influence fracture union status. CONCLUSIONS: The rate of nonunion after operatively treated long-bone fractures was 9.4%. In this cohort, use of a bisphosphonate or SERM/HRT was not associated with fracture union status at 1 year. Orthopaedic surgeons should not withhold or delay initiating medical therapies for osteoporosis in the setting of acute fracture out of concern for nonunion. LEVEL OF EVIDENCE: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Thorne TJ, Steffenson L, O'Neill DC, et al. No Increased Risk of Nonunion with Bisphosphonate Use in a Medicare Claims Cohort Following Operatively Treated Long-Bone Fractures. J Bone Joint Surg Am. 2023. PMID: 36753557. doi:10.2106/JBJS.22.01127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。